imugene ceo hails clinical milestone for her-vaxx cancer immunotherapy
Published 3 years ago • 2.2K plays • Length 6:15Download video MP4
Download video MP3
Similar videos
-
4:45
imugene thrilled with ethics approval for phase 2 her-vaxx trial
-
32:59
imugene's science series: pd1-vaxx | b cell immunotherapy
-
4:49
imugene her-vaxx video asx: imu | an emerging leader in cancer immuno-oncology
-
4:27
imugene pd1 vaxx 1080p
-
27:13
imugene investor webinar: mast study update
-
20:37
imugene (asx: imu) – the ‘holy grail’ of cancer treatment…?! | asx ceo interview 🚀📈
-
8:59
imugene officially announce their her-vaxx trial results
-
24:02
imugene forges development path of immunotherapies and cancer-killing virus
-
7:40
imugene limited (asx: imu) emergence 2024: presentation by leslie chong, managing director and ceo
-
25:53
imugene ceo leslie chong's presentation at the nwr virtual investor conference august 2021.
-
0:37
imugene's science series: pd1-vaxx (intro)
-
39:40
imugene investor webinar with special guests bradley glover and paul woodard
-
6:29
imugene finishes phase 1a monotherapy dose escalation of pd1 vaxx
-
4:51
'the why' | imugene, developing cancer immunotherapies asx: imu
-
26:56
investor presentation post asx news: imugene and eureka therapeutics oncarlytics collaboration
-
5:42
july 8 2019 her-vaxx esmo interview | proactive investors
-
3:58
car t explained
-
0:51
meet tilanthi jayawardena, imugene’s translational sciences lead for azer-cel.
-
5:20
first patient in nextherizon phase 2 clinical trial